FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282941907> ?p ?o ?g. }

• W4282941907 endingPage "e172" @default.
• W4282941907 startingPage "e172" @default.
• W4282941907 abstract "Objective: Endothelial dysfunction is thought to underlie many of the complications of COVID-19 but to what degree this persists after recovery is unknown. Here we examine endothelial function in subjects previously hospitalized with COVID-19, those with mild symptoms who were not hospitalized and negative controls (absence of SARS-CoV-2-antibodies). Endothelial function was measured as pulse wave response to the 2 adrenergic agonist salbutamol (PWRS) which is mediated through the nitric oxide - cyclic guanosine monophosphate pathway (NO-cGMP). Design and method: Echocardiography was used to exclude subjects with cardiac abnormalities. Tonometry of the radial artery (SphygmoCor, AtCor Medical, Sydney, Australia) was performed in duplicate by a single operator before and after inhalation of 200 mcg of salbutamol using a spacer device. The PWRS was taken as the change from baseline in augmentation index (Aix) as calculated by the SphygmoCor system. In a sub-sample, PWRS was assessed in the presence and absence of the phosphodiesterase type 5 inhibitor sildenafil which inhibits the breakdown of cGMP. Results: We recruited 88 subjects (49 men) aged 47.9 ± 14.3 (mean ± SD) years of whom 32 were previously hospitalized with COVID-19 (~6 months). Subjects previously hospitalized with COVID-19 were all previously assessed in a dedicated pulmonary clinic. Age, gender, BMI, smoking status, diabetes and estimated 10-year cardiovascular risk (Q-RISKâ3) were similar between the groups. Administration of salbutamol reduced AIx in controls and those with mild COVID-19 but produced an increase in AIx in previously hospitalized COVID-19 cases (mean [95% CI]): -2.85 [-5.52, -0.188] %, -2.32 [-5.17,0.54] %, and 3.03 [0.06, 6.00] % respectively, P = 0.017 between the groups. In a sub-sample (11 hospitalized and 11 non-hospitalized) the PWRS was measured again 30 minutes after oral administration of sildenafil 25 mg. This produced a greater reduction in AIx: -5.28 [-9.00, -1.54] % in non-hospitalized and a reduction: -3.90 [-7.60, -0.21] % in hospitalized patients, and an overall improvement in the PWRS (P = 0.006). Conclusions: In subjects previously hospitalized with severe COVID-19, endothelial function is impaired for many months after hospital discharge and the impaired NO-cGMP mediated vasodilation may be reversed by sildenafil." @default.
• W4282941907 created "2022-06-16" @default.
• W4282941907 creator A5039990900 @default.
• W4282941907 creator A5041837237 @default.
• W4282941907 creator A5068540141 @default.
• W4282941907 creator A5075056333 @default.
• W4282941907 creator A5082445800 @default.
• W4282941907 date "2022-06-01" @default.
• W4282941907 modified "2023-09-25" @default.
• W4282941907 title "IMPAIRED BETA-2ADRENERGIC ENDOTHELIUM-DEPENDENT VASODILATION IS REVERSED BY PHOSPHODIESTERASE INHIBITION IN PATIENTS PREVIOUSLY HOSPITALIZED WITH COVID-19" @default.
• W4282941907 doi "https://doi.org/10.1097/01.hjh.0000837128.02128.92" @default.
• W4282941907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36027033" @default.
• W4282941907 hasPublicationYear "2022" @default.
• W4282941907 type Work @default.
• W4282941907 citedByCount "0" @default.
• W4282941907 crossrefType "journal-article" @default.
• W4282941907 hasAuthorship W4282941907A5039990900 @default.
• W4282941907 hasAuthorship W4282941907A5041837237 @default.
• W4282941907 hasAuthorship W4282941907A5068540141 @default.
• W4282941907 hasAuthorship W4282941907A5075056333 @default.
• W4282941907 hasAuthorship W4282941907A5082445800 @default.
• W4282941907 hasBestOaLocation W42829419071 @default.
• W4282941907 hasConcept C126322002 @default.
• W4282941907 hasConcept C134018914 @default.
• W4282941907 hasConcept C164705383 @default.
• W4282941907 hasConcept C2776042228 @default.
• W4282941907 hasConcept C2777394947 @default.
• W4282941907 hasConcept C2780972559 @default.
• W4282941907 hasConcept C2780994212 @default.
• W4282941907 hasConcept C519581460 @default.
• W4282941907 hasConcept C71924100 @default.
• W4282941907 hasConcept C75603125 @default.
• W4282941907 hasConceptScore W4282941907C126322002 @default.
• W4282941907 hasConceptScore W4282941907C134018914 @default.
• W4282941907 hasConceptScore W4282941907C164705383 @default.
• W4282941907 hasConceptScore W4282941907C2776042228 @default.
• W4282941907 hasConceptScore W4282941907C2777394947 @default.
• W4282941907 hasConceptScore W4282941907C2780972559 @default.
• W4282941907 hasConceptScore W4282941907C2780994212 @default.
• W4282941907 hasConceptScore W4282941907C519581460 @default.
• W4282941907 hasConceptScore W4282941907C71924100 @default.
• W4282941907 hasConceptScore W4282941907C75603125 @default.
• W4282941907 hasIssue "Suppl 1" @default.
• W4282941907 hasLocation W42829419071 @default.
• W4282941907 hasLocation W42829419072 @default.
• W4282941907 hasLocation W42829419073 @default.
• W4282941907 hasOpenAccess W4282941907 @default.
• W4282941907 hasPrimaryLocation W42829419071 @default.
• W4282941907 hasRelatedWork W1976668668 @default.
• W4282941907 hasRelatedWork W2008087125 @default.
• W4282941907 hasRelatedWork W2042780225 @default.
• W4282941907 hasRelatedWork W2116538667 @default.
• W4282941907 hasRelatedWork W2145618820 @default.
• W4282941907 hasRelatedWork W2161501502 @default.
• W4282941907 hasRelatedWork W2293278356 @default.
• W4282941907 hasRelatedWork W2409608972 @default.
• W4282941907 hasRelatedWork W2588617533 @default.
• W4282941907 hasRelatedWork W2792027682 @default.
• W4282941907 hasVolume "40" @default.
• W4282941907 isParatext "false" @default.
• W4282941907 isRetracted "false" @default.
• W4282941907 workType "article" @default.